The U.S. House of Representatives recently passed the Lower Costs, More Transparency Act. The act aims to reduce health care costs through several mechanisms including increasing access to generic drugs, and mandating greater transparency in the pricing of medical procedures and the costs associated with prescription medications.
The vote resulted in the approval of the bill with a significant 320-to-71 majority. Highlighting the bipartisan footing, the bill’s sponsors cover both ends of the political landscape, including Representatives McMorris Rodgers (R-Washington), Pallone (D-New Jersey), Smith (R-Missouri), and Foxx (R-North Carolina).
One of the main strategies of the proposed legislation is imposing a requirement on various entities within the health industry such as hospitals, insurance companies, labs, and pharmacies to disclose their pricing to the public. Furthermore, the Act stipulates that insurance companies and Pharmacy Benefit Managers (PBMs) share details of their negotiated drug rebates and discounts.
The Lower Costs, More Transparency Act also reaches towards improving access to lower-cost options, such as giving seniors the ability to access prescription drugs via a hospital-owned outpatient facility at a reduced out-of-pocket cost.
According to a statement by Pallone, “This bipartisan bill is a victory for everyone who has ever struggled to navigate and understand the cost of a health care procedure or a prescription drug.” Smith echoed these sentiments, underscoring the empowerment this Act brings to patients by fostering a more transparent health care system.
The move by the House received applause from various advocacy organizations, notably Patients for Affordable Drugs Now and Better Solutions for Healthcare, both of which have expressed optimism for similar action in the Senate.
Now, the Lower Costs, More Transparency Act will advance to the Senate, bringing heightened price transparency a step closer to reality for the American healthcare system. An easy passage echoes the commitment towards a more inclusive health care environment and could significantly impact future dealings in the sector.
For more insight into the development and implications of the Act, see the original article here.